retatrutide mechanism triple agonist gip glp-1 glucagon receptor π A triple-action once-weekly injection can significantly lower blood sugar and body weight in people with type 2 diabetes, a new phase 3 trial shows. is part of an emerging generation retatrutide gip glp-1 glucagon receptor
Pay in 4 interest-free payments of $6.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 28 - Sep 2


























